'Drug classes' presentation slideshows

Management of Neuropathic Pain

Management of Neuropathic Pain. Mellar P Davis MASCC ,June 2009. Pharmacological treatment of neurologic pain relies on evidence from large randomized controlled trials. Attal 2006 Dworkin 2007.

793 views • 58 slides

Maternal & Newborn Effects of Perinatal Substance Abuse

2010 Health Summit Substance Abuse and Pregnancy Charlottesville, Virginia. Maternal & Newborn Effects of Perinatal Substance Abuse. Michael Weaver, MD, FASAM Division of Addiction Psychiatry Virginia Commonwealth University Medical Center. Objectives. Substance use and pregnancy

991 views • 50 slides

Transitions: Moving Dual Eligibles to Medicare Prescription Drug Coverage

Transitions: Moving Dual Eligibles to Medicare Prescription Drug Coverage. Tony Culotta, Director, Appeals and Enrollment Group Babette Edgar, Director, Division of Finance and Operations, Medicare Drug Benefit Group Alissa DeBoy, Special Assistant, Medicare Drug Benefit Group.

586 views • 46 slides

Drug Matrix DB: a Large T oxicogenomic R eference R esource

Drug Matrix DB: a Large T oxicogenomic R eference R esource. B. Alex Merrick, Ph.D. Division, National Toxicology Program National Institute of Environmental Health Sciences. Outline. Part 1: General Introduction to DrugMatrix and ToxFX Part 2: Overview of the DrugMatrix Database. 2.

775 views • 40 slides

The Macstrak Project

Medication Classification. The Macstrak Project. Issues. Macstrak follows drug interventions by drug class rather than the specific agent (e.g. B blocker po rather than metoprolol) to get reliable data first need to ensure understanding of where data captured on Macstrak form

582 views • 37 slides

Transparency in Clinical Trials and its Impact on the Intelligence Community

564 views • 34 slides

Culture and Sensitivity Helping the Infection Preventionist Interpret Antibiograms

Culture and Sensitivity Helping the Infection Preventionist Interpret Antibiograms. Walter Phillips, BS, MS, PhD Director of Microbiology TriStar Healthcare System. Acknowledge. I would like to acknowledge the following contributors to this presentation:

491 views • 29 slides

Toxicology Laboratory Updates

Toxicology Laboratory Updates. Washington State Toxicology Lab Washington State Patrol Brian Capron. Laboratory Staffing Updates. New Laboratory Manger: Dr. Brianna Peterson Two toxicologists still on maternity leave Lisa Noble (return November) Rebecca Flaherty (return December)

468 views • 26 slides

Present therapeutic targets in HIV life cycle

Possible Biomedical Informatics pilot study Integration of viral genomics with clinical data in HIV infection. Present therapeutic targets in HIV life cycle. ATTACHMENT. Nucleoside RT Inhibitors (NRTI). FUSION. Fusion inhibitors. Non-nucleoside RT inhibitors (NNRTI). UNCOATING.

398 views • 26 slides

Psychiatry Clerkship

Psychiatry Clerkship. PSRY 5000. Kimberly W. Curtis Clerkship Coordinator. What we expect . . . Attendance When absent, inform attending, resident(s), and clerkship coordinator Dress code Professional attire, white coats (no scrubs), GHSU ID

385 views • 24 slides

Antibacterial susceptibility testing

Antibacterial susceptibility testing. Drug classes Methods for testing Laboratory strategies. Basic principles of antimicrobial action. 1. Agent is in active form - pharmacodynamics: structure & route 2. Achieve sufficient levels at site of infection - pharmacokinetics.

384 views • 24 slides

Ranking of Antimicrobial Drugs According to Importance in Human Medicine

Ranking of Antimicrobial Drugs According to Importance in Human Medicine. John H. Powers, M.D. Lead Medical Officer Antimicrobial Drug Development and Resistance Initiatives Office of Drug Evaluation IV Center for Drug Evaluation and Research U.S. Food and Drug Administration. Introduction.

399 views • 21 slides

278 views • 20 slides

The New Pricing and Reimbursement of Pharmaceuticals in Italy Prof. Fabrizio Gianfrate LUISS University & Business

647 views • 19 slides

Abuse Liability and Drug Scheduling: The Role of the FDA Deborah B. Leiderman, M.D. Director, Controlled Substance St

Abuse Liability and Drug Scheduling: The Role of the FDA Deborah B. Leiderman, M.D. Director, Controlled Substance Staff CDER/FDA. January 30-31, 2002. Abuse Potential Assessment. Federal Food, Drug and Cosmetic Act (FD&C Act, 1938) Determination of Abuse Potential

537 views • 18 slides

GAP Toolkit 5 Training in basic drug abuse data management and analysis

GAP Toolkit 5 Training in basic drug abuse data management and analysis. Training session 6 Coding open questions. Objectives. To distinguish between the coding of open and closed questions To establish a set of practical coding rules for open questions

197 views • 18 slides

Bacterial Resistance Problem Space

Bacterial Resistance Problem Space. Ehren Bucholtz Saint Mary-of-the-Woods College Mark Gallo Niagara University. Background. Microbial drug resistance (DR) is a growing concern among health professionals and others around the world.

318 views • 16 slides

Medicaid Prescription Drug Purchasing: Preferred Drug List Proposed Final Report

Medicaid Prescription Drug Purchasing: Preferred Drug List Proposed Final Report. Joint Legislative Audit & Review Committee July 22, 2009 John Bowden, JLARC Staff. PROGRAM BACKGROUND. What is the State Preferred Drug List?.

242 views • 9 slides

POLYPHARMACIA

POLYPHARMACIA. Pat Borman, MD Advanced Training in Geriatrics. Case Example: Mr. Powers.

179 views • 7 slides